Serum concentration of hepatocyte growth factor as a biomarker for the clinical response to anti-PD-1 antibody therapy in patients with metastatic melanoma
Latest Information Update: 10 Sep 2019
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 10 Sep 2019 New trial record